Stoke Therapeutics (NASDAQ:STOK) Insider Sells $27,494.16 in Stock

Posted by Stanley Muller on Oct 5th, 2026

Stoke Therapeutics, Inc. (NASDAQ:STOK – Get Free Report) insider Barry Ticho sold 1,051 shares of the company’s stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $26.16, for a total transaction of $27,494.16. Following the completion of the transaction, the insider owned 19,059 shares in the company, valued at approximately $498,583.44. This represents a 5.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Barry Ticho also recently made the following trade(s):

On Tuesday, September 1st, Barry Ticho sold 5,545 shares of Stoke Therapeutics stock. The shares were sold at an average price of $30.67, for a total transaction of $170,065.15.
On Tuesday, August 18th, Barry Ticho sold 4,767 shares of Stoke Therapeutics stock. The shares were sold at an average price of $32.03, for a total value of $152,687.01.
On Monday, August 3rd, Barry Ticho sold 7,176 shares of Stoke Therapeutics stock. The shares were sold at an average price of $29.04, for a total value of $208,391.04.

Stoke Therapeutics Price Performance

NASDAQ:STOK opened at $25.62 on Monday. Stoke Therapeutics, Inc. has a 52 week low of $20.32 and a 52 week high of $40.22. The stock’s fifty day moving average is $29.91 and its two-hundred day moving average is $31.15. The stock has a market capitalization of $1.65 billion, a price-to-earnings ratio of -7.67 and a beta of 1.26.

Stoke Therapeutics (NASDAQ:STOK – Get Free Report) last issued its quarterly earnings data on Monday, August 3rd. The company reported ($0.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.13). The firm had revenue of $9.32 million during the quarter, compared to analyst estimates of $4.89 million. Stoke Therapeutics had a negative net margin of 753.60% and a negative return on equity of 59.36%. On average, sell-side analysts expect that Stoke Therapeutics, Inc. will post -3.52 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have issued reports on STOK shares. Wedbush boosted their price target on shares of Stoke Therapeutics from $38.00 to $40.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 4th. Chardan Capital reissued a “buy” rating and issued a $35.00 price objective on shares of Stoke Therapeutics in a research note on Tuesday, August 4th. The Goldman Sachs Group reissued a “buy” rating on shares of Stoke Therapeutics in a research note on Thursday, September 10th. Canaccord Genuity Group dropped their price objective on shares of Stoke Therapeutics from $60.00 to $58.00 and set a “buy” rating for the company in a report on Tuesday, August 4th. Finally, JPMorgan Chase & Co. began coverage on shares of Stoke Therapeutics in a research note on Friday, August 21st. They set an “overweight” rating and a $40.00 target price on the stock. Ten investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $44.25.

Get Our Latest Stock Analysis on STOK

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Quantbot Technologies LP acquired a new position in Stoke Therapeutics in the second quarter valued at approximately $34,000. KBC Group NV purchased a new position in Stoke Therapeutics in the first quarter valued at approximately $36,000. Harbour Investments Inc. raised its holdings in Stoke Therapeutics by 312.9% during the fourth quarter. Harbour Investments Inc. now owns 1,185 shares of the company’s stock worth $38,000 after purchasing an additional 898 shares in the last quarter. Western Wealth Management LLC acquired a new stake in Stoke Therapeutics during the first quarter worth approximately $55,000. Finally, EverSource Wealth Advisors LLC raised its holdings in Stoke Therapeutics by 195.3% during the first quarter. EverSource Wealth Advisors LLC now owns 1,837 shares of the company’s stock worth $60,000 after purchasing an additional 1,215 shares in the last quarter.

About Stoke Therapeutics

(Get Free Report)

Stoke Therapeutics, Inc is a biotechnology company developing genetic medicines for severe diseases caused by inadequate protein expression. The company’s approach, known as TANGO (Targeted Augmentation of Nuclear Gene Output), uses antisense oligonucleotides to selectively modulate pre-messenger RNA splicing and increase production of functional proteins from disease-associated genes.

Stoke’s lead program is zorevunersen (STK-001), an investigational antisense oligonucleotide designed to increase functional NaV1.1 protein expression in people with Dravet syndrome, a severe genetic epilepsy caused primarily by mutations in the SCN1A gene.